Long-Term Treatment With Interleukin-6 Receptor Inhibitor Tocilizumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
Data about efficacy and safety of disease-modifying therapeutic options in myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) are scarce. Interleukin-6 signaling has been suggested to be involved in the pathogenesis of MOGAD. The aim of this study was to evaluate the effectiveness and safety of the interleukin-6 receptor inhibitor tocilizumab (TCZ) in MOGAD.
Authors
- Veronika Kana (ORCID: https://orcid.org/0000-0002-9362-3156)
- Francesco Capecchi (ORCID: https://orcid.org/0000-0002-5803-7573)
- Nathalie Nierobisch (ORCID: https://orcid.org/0009-0005-0992-6867)
- Sinan Yasaroglu
- Madalina Graure
- Salome Schubert
- Patrick Roth
- Michael Weller
Institutions
- University of Zurich (CH)
- TUM Klinikum (DE)
- ETH Zurich (CH)
- University Hospital of Zurich (CH)
Publication Details
- Journal
- Neurology Open Access
- Published
- 2026-02-09
- DOI
- https://doi.org/10.1212/wn9.0000000000000049
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00